Beta
ManageSearchChatDiscover
271642

ASTRAZENECA AND SINOPHARM VACCINES ADVERSE EFFECTS AT FIRST AND SECOND DOSES. CROSS SECTIONAL STUDY EGYPTIAN EXPERIENCE

Article

Last updated: 25 Dec 2024

OverviewSimilar Items

Subjects

-

Tags

-

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that causes severe acute respiratory syndrome (SARS). It was discovered in December 2019 in Wuhan, China., which subsequently led to a nationwide outbreak. The World Health Organization included the AstraZeneca  and Sinopharm vaccines for the WHO Emergency Use List on February 16 and May 7, 2021, respectively. Egyptians have gotten 2,623,200 doses of AstraZeneca's COVID-19 vaccination plus  500,000 doses of Sinopharm vaccine. The trial would test the vaccinations' short-term side effects on Egyptian people aged 18 and older. Results: Most symptoms decreased significantly after the second dose when compared to symptoms seen at the first dose .In addition, both doses reduced symptoms significantly compared to the first dose.Interestingly, the desire to sleep appears to significantly increase the side effects again after both doses when compared to the second dose alone. The majority or nearly all of the participants (96.5%) had no infection after vaccination. Conclusion: Mild to moderate side effects are to be expected after the vaccination process because the body's immunomodulatory instructions can lead to negative symptoms. Symptoms include injection site soreness, fever, tiredness, headache, muscle aches, chills, and diarrhoea.. The majority or nearly all of the participants (96.5%) had no infection after vaccination. Training and continuing education are needed to improve universal vaccine acceptance and reduce frequency.

DOI

10.21608/bfsa.2022.271642

Keywords

Vaccination, AstraZeneca, Sinopharm, Egyptian population

Authors

First Name

Noha

Last Name

El-Bassiouny

MiddleName

A.

Affiliation

Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Damanhour University, Egypt

Email

noha.el.bassiouny@pharm.dmu.edu.eg

City

-

Orcid

0000-0001-9277-2910

First Name

Amira

Last Name

Kassem

MiddleName

B.

Affiliation

Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Damanhour University, Egypt

Email

amira.kassem@pharm.dmu.edu.eg

City

-

Orcid

0000-0003-4195-6036

First Name

Mohammad

Last Name

Abd-Alhaseeb

MiddleName

M

Affiliation

Department of Pharmacology and toxicology, Faculty of Pharmacy, Damanhour University, Egypt

Email

-

City

-

Orcid

-

First Name

Marwa

Last Name

Tolba

MiddleName

Kamal

Affiliation

Clinical pharmacy department, faculty of pharmacy, fayoum universit, fayoum, egypt

Email

mka05@fayoum.edu.eg

City

Fayoum

Orcid

0000-0002-3261-0327

Volume

45

Article Issue

2

Related Issue

37882

Issue Date

2022-12-01

Receive Date

2022-03-24

Publish Date

2022-12-01

Page Start

801

Page End

809

Print ISSN

1110-0052

Online ISSN

3009-7703

Article File

BFSA_Volume 45_Issue 2_Pages 801-809.pdf

PDF . 891.9kB

Link

https://bpsa.journals.ekb.eg/article_271642.html

Detail API

https://bpsa.journals.ekb.eg/service?article_code=271642

Order

271,642

Type

Original Article

Type Code

1,096

Publication Type

Journal

Publication Title

Bulletin of Pharmaceutical Sciences Assiut University

Publication Link

https://bpsa.journals.ekb.eg/

MainTitle

ASTRAZENECA AND SINOPHARM VACCINES ADVERSE EFFECTS AT FIRST AND SECOND DOSES. CROSS SECTIONAL STUDY EGYPTIAN EXPERIENCE

Details

Type

Article

Created At

22 Jan 2023